ArticleAmerican heart journal2010
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
Article in American heart journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00202878. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)
Open the trial in the graphWho cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.The Cochrane database of systematic reviews · 2018 · on this mapPooled it
- Medication Discontinuation in the IMPROVE-IT Trial.Circulation. Cardiovascular quality and outcomes · 2019Trial
- Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.Lipids in health and disease · 2010Trial
- Evolving targets for lipid-modifying therapy.EMBO molecular medicine · 2014Review
- Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.Current atherosclerosis reports · 2014Review
- Origin and therapy for hypertriglyceridaemia in type 2 diabetes.World journal of diabetes · 2014Review
- Testing cardiovascular drug safety and efficacy in randomized trials.Circulation research · 2014Review
- Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.Vascular health and risk management · 2014Article
- Demystifying the management of hypertriglyceridaemia.Nature reviews. Cardiology · 2013Review
- Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.Vascular health and risk management · 2013Observational
- Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia.Current therapeutic research, clinical and experimental · 2012Article
- Ezetimibe therapy: mechanism of action and clinical update.Vascular health and risk management · 2012Review
- Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.Lipids in health and disease · 2011Article
- Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?Circulation · 2011Article
- Pharmacological strategies for lowering LDL cholesterol: statins and beyond.Nature reviews. Cardiology · 2011Review
- Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2011Article
- Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?Current atherosclerosis reports · 2011Article
- What combination therapy with a statin, if any, would you recommend?Current atherosclerosis reports · 2011Review
- Therapies targeting exogenous cholesterol uptake: new insights and controversies.Current atherosclerosis reports · 2011Review
- Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.Vascular health and risk management · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20435175What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.